Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference Transcript
Just want to welcome everyone to the Cowen 43rd Annual Healthcare Conference. I'm Troy Langford, one of biotech private associates on the TD Cowen team. It is my pleasure today to introduce to Tony Coles, CEO of Cerevel. He's going to give a corporate update. So take it away, Tony.
Thanks, Troy, and good morning to everyone on here in the room and listening on the webcast. It's my privilege to be here, opening up the conference to tell you the exciting story of Cerevel Therapeutics, who happens to be five years old, that has an amazing amount of progress in those few short years.
I'd like to remind you that I will be making some forward-looking statements, so please refer to our various SEC documents for additional details and provisos.
The simple underlying thesis or hypothesis for Cerevel lies in the scientific notion that the brain is wired in a very particular way with regards to neuro transmitters and neuro receptors. This
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
